News from the FDA/CDC

FDA issues warnings to companies selling illegal Alzheimer’s treatments


 

The Food and Drug Administration has issued warning letters to 12 companies and advisory letters to 5 companies illegally selling more than 58 products claiming to treat Alzheimer’s disease.

FDA icon Wikimedia Commons/FitzColinGerald/Creative Commons License

The products, many of which are marketed as dietary supplements, are being sold in a variety of forms, including tablets, capsules, and oils. These drugs are either unapproved or mislabeled and claim to prevent, treat, or cure Alzheimer’s disease, as well as a number of other serious diseases and health conditions, in violation of the Federal Food, Drug, and Cosmetic Act.

“Alzheimer’s is a challenging disease that, unfortunately, has no cure. Any products making unproven drug claims could mislead consumers to believe that such therapies exist and keep them from accessing therapies that are known to help support the symptoms of the disease, or worse, as some fraudulent treatments can cause serious or even fatal injuries,” FDA Commissioner Scott Gottlieb, MD, said in a press release.

In an additional statement, Dr. Gottlieb detailed several new strategies for improving the safety and accuracy of dietary supplements, including efforts to more rapidly communicate to the public potential safety issues with dietary supplement products and to establish a flexible regulatory framework that promotes innovation and upholds product safety.

Recommended Reading

Cerebral small vessel disease progression linked to MCI in hypertensive patients
MDedge Neurology
Nuedexta mainly prescribed for dementia, Parkinson’s
MDedge Neurology
Researchers exploring ways to mitigate aging’s impact on diabetes
MDedge Neurology
Treating OSA with positive airway pressure decreased amyloid levels in CSF
MDedge Neurology
As deep sleep decreases, Alzheimer’s pathology – particularly tau – increases
MDedge Neurology
Frailty may affect the expression of dementia
MDedge Neurology
SPRINT MIND published: Extension trial to add 2 years’ follow-up
MDedge Neurology
Phase 3 studies of antiamyloid Alzheimer’s drug crenezumab stopped
MDedge Neurology
Aerobic exercise may mitigate age-related cognitive decline
MDedge Neurology
Novel plasma biomarkers may predict preclinical Alzheimer’s disease
MDedge Neurology